2. Others Immunology/Inflammation Anti-infection Apoptosis
  3. Parasite TNF Receptor Interleukin Related Environmental Pollutants Apoptosis
  4. Pentadecane

Pentadecane is an orally active natural plant volatile alkane with anti-inflammatory, analgesic, antipyretic and anti-leishmanial activities. Pentadecane presents IC50 values of 65.3 μM, 60.5 μM and 194.8 μM against Leishmania infantum promastigotes, amastigotes and intracellular amastigotes, respectively. Pentadecane downregulates the mRNA expression of TNF-α and IL-12 and inhibits the release of inflammatory mediators. Pentadecane arrests the cell cycle of Leishmania infantum and induces apoptosis. Pentadecane can be applied to the research of inflammation and leishmaniasis.

For research use only. We do not sell to patients.

Pentadecane

Pentadecane Chemical Structure

CAS No. : 629-62-9

Size Price Stock Quantity
Liquid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Liquid
100 g In-stock
250 g In-stock
500 g In-stock
1 kg In-stock

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Pentadecane:

Pentadecane Related Antibodies

Top Publications Citing Use of Products

View All Parasite Isoform Specific Products:

View All Isoforms
Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

View All TNF Receptor Isoform Specific Products:

View All Isoforms
TNFRSF1A/CD120a TNFRSF3/CD18 TNFRSF4 TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF7/CD27 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF10B/DR5/CD262 TNFRSF12A/TWEAK TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Pentadecane is an orally active natural plant volatile alkane with anti-inflammatory, analgesic, antipyretic and anti-leishmanial activities. Pentadecane presents IC50 values of 65.3 μM, 60.5 μM and 194.8 μM against Leishmania infantum promastigotes, amastigotes and intracellular amastigotes, respectively. Pentadecane downregulates the mRNA expression of TNF-α and IL-12 and inhibits the release of inflammatory mediators. Pentadecane arrests the cell cycle of Leishmania infantum and induces apoptosis. Pentadecane can be applied to the research of inflammation and leishmaniasis[1][2][3].

IC50 & Target[1][3]

IL-12

 

TNF-α

 

Leishmania

 

In Vitro

Pentadecane (10-60 µg/mL; overnight) does not inhibit the growth of Staphylococcus aureus, Bacillus subtilis, Escherichia coli, or Pseudomonas aeruginosa[1].
Pentadecane (60 µg/mL; 8 h) temporarily inhibits the growth of Staphylococcus aureus, Bacillus subtilis, Escherichia coli, and Pseudomonas aeruginosa over an 8-hour period, but does not prevent long-term bacterial growth[1].
Pentadecane (10-70 µg/mL; 48 h pre-incubation, followed by 48 h LPS/IFN-γ stimulation) significantly downregulates TNF-α and IL-12 mRNA expression in LPS/IFN-γ-induced M1 phenotype U937 macrophages, with the most potent TNF-α inhibition seen at 10 µg/mL in hexane[1].
Pentadecane (50-300 μM; 48 h) inhibits the viability of Leishmania infantum promastigotes (IC50 = 65.3 μM) and axenic amastigotes (IC50 = 60.5 μM) in a dose-dependent manner[3].
Pentadecane (65.3-300 μM; 48 h) induces apoptotic-like morphological changes (loss of cell volume, nuclear condensation) in Leishmania infantum promastigotes[3].
Pentadecane (65.3 μM; 24 h) induces cell cycle arrest in Leishmania infantum promastigotes, increasing the proportion of cells in the sub-G0/G1 phase and eliminating cells in the G2/M phase[3].
Pentadecane (50-300 μM; 48 h) causes negligible cytotoxicity in DH82 dog macrophage cells, U937 human histiocytic lymphoma cells, and normal CPE primary epithelial cells[3].
Pentadecane (300 μM; 48 h) inhibits the growth of Leishmania infantum intracellular amastigotes in U937-derived macrophages, reducing infection by 77% at 300 μM and exhibiting an IC50 of 194.8 μM[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pentadecane Related Antibodies

Real Time qPCR[1]

Cell Line: LPS/IFN-γ-induced M1 phenotype U937 human monocytic macrophages
Concentration: 10, 70 µg/mL
Incubation Time: 48 h pre-incubation, followed by 48 h LPS/IFN-γ stimulation
Result: Showed the most significant downregulation of TNF-α mRNA expression at 10 µg/mL (hexane) compared to the LPS-treated M1 control.
Significantly downregulated IL-12 mRNA expression at all tested concentrations compared to the LPS-treated M1 control.
Showed no significant difference in IL-12 mRNA expression from the 10% hexane control group at 70 µg/mL (hexane).

Cell Viability Assay[1]

Cell Line: human dermal fibroblast (HDF) cells
Concentration: 10, 20, 30, 40, 50, 60, 70 µg/mL
Incubation Time: 48 h
Result: Resulted in average cell viability between 58% and 103%, with viability averagely higher than cells treated with palmitic acid.

Cell Viability Assay[3]

Cell Line: DH82 dog macrophage cells, U937 human histiocytic lymphoma cells, primary epidermal cells of CPE
Concentration: 50 μM, 100 μM, 150 μM, 200 μM, 250 μM, 300 μM
Incubation Time: 48 h
Result: Maintained DH82 cell viability between ~78% and ~94%.
Maintained CPE cell viability between ~84% and ~122%.
Maintained U937 cell viability between ~86% and ~137%.
Resulted in all tested cell lines showing viability higher than 60% across all concentrations, indicating negligible cytotoxicity.
In Vivo

Pentadecane (1000 mg/kg; p.o.; daily; 14 days) shows no apparent acute toxicity in Sprague-Dawley rats at an oral dose of 1000 mg/kg daily for 14 days[2].
Pentadecane (5, 10 mg/kg; p.o.; single dose) exhibits significant dose-dependent analgesic activity in the acetic acid-induced writhing model in Sprague-Dawley rats[2].
Pentadecane (5, 10 mg/kg; p.o.; single dose) exhibits significant analgesic activity targeting inflammatory nociception in the formalin-induced paw licking model in Sprague-Dawley rats[2].
Pentadecane (5, 10 mg/kg; p.o.; single dose) exhibits significant anti-inflammatory activity in the carrageenan-induced paw edema model in Sprague-Dawley rats[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Molecular Weight

212.41

Formula

C15H32
CAS No.
Appearance

Liquid (Density: 0.769 g/cm3)

Color

Colorless to off-white

SMILES

CCCCCCCCCCCCCCC
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Store at room temperature 3 years

In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (470.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.7079 mL 23.5394 mL 47.0788 mL
5 mM 0.9416 mL 4.7079 mL 9.4158 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (11.77 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (11.77 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 98.88%

SDS (623 KB)

COA (237 KB) HNMR (115 KB) GC (195 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 4.7079 mL 23.5394 mL 47.0788 mL 117.6969 mL
5 mM 0.9416 mL 4.7079 mL 9.4158 mL 23.5394 mL
10 mM 0.4708 mL 2.3539 mL 4.7079 mL 11.7697 mL
15 mM 0.3139 mL 1.5693 mL 3.1386 mL 7.8465 mL
20 mM 0.2354 mL 1.1770 mL 2.3539 mL 5.8848 mL
25 mM 0.1883 mL 0.9416 mL 1.8832 mL 4.7079 mL
30 mM 0.1569 mL 0.7846 mL 1.5693 mL 3.9232 mL
40 mM 0.1177 mL 0.5885 mL 1.1770 mL 2.9424 mL
50 mM 0.0942 mL 0.4708 mL 0.9416 mL 2.3539 mL
60 mM 0.0785 mL 0.3923 mL 0.7846 mL 1.9616 mL
80 mM 0.0588 mL 0.2942 mL 0.5885 mL 1.4712 mL
100 mM 0.0471 mL 0.2354 mL 0.4708 mL 1.1770 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Pentadecane Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Pentadecane629-62-9ParasiteTNF ReceptorInterleukin RelatedEnvironmental PollutantsApoptosisTumor Necrosis Factor ReceptorTNFRILEnvironmental ContaminantsIL-12human dermal fibroblast cellsSprague-Dawley ratsTNF-αpromastigotesamastigotesU937 macrophagesStaphylococcus aureusLeishmania infantumEscherichia coliInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Pentadecane
Cat. No.:
HY-N7926
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (623 KB) Français - FR (623 KB) Deutsch - DE (623 KB) Norwegian - NO (623 KB) Español - ES (623 KB) Swedish - SV (623 KB) Italian - IT (623 KB) Korean - KR (623 KB) Portuguese - PT (623 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.